Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors

Inclusion Criteria:

* Confirmed diagnosis of:

  * Advanced solid tumor that is no longer responding to therapies OR
  * Advanced or recurrent endometrial carcinoma OR
  * Advanced or recurrent ovarian carcinoma OR
  * Unresectable (Stage IIIB or IV) NSCLC
* ECOG Performance Status 0-1 (ECOG status of 2 may be considered following discussion and agreement with sponsor)
* Adequate organ and bone marrow function as defined by hematological and serum chemistry limits
* At least 18 years old
* Both men and women must practice adequate contraception
* Informed consent

Exclusion Criteria:

* Restriction of some therapies/medications within specific timeframes prior to enrollment and during the study including prior therapy with PI3K, AKT, or mTOR inhibitors, cytotoxic chemotherapy, biologic agents, nitrosoureas or mitomycin C, small-molecule kinase inhibitors, non-cytotoxic hormonal agents
* Known allergy or hypersensitivity to any of the components of the treatment formulations
* Taking oral corticosteroids chronically or \> 1 mg/day warfarin
* Not recovered from the toxic effects of prior therapy
* History of diabetes mellitus.
* Uncontrolled intercurrent illness
* Pregnant or breastfeeding
* Congestive heart failure, unstable angina, or a myocardial infarction within 3 months of entering the study.
* HIV positive
* Diagnosis of another malignancy may exclude subject from study